INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 3,874 | $322.34 | 1,077,165 |
| Dec 19, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,562 | $21.92 | 1,076,998 |
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,490 | $323.42 | 1,075,675 |
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,700 | $324.61 | 1,073,975 |
| Dec 19, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,952 | $16.80 | 1,072,436 |
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,932 | $325.44 | 1,072,043 |
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 2,100 | $326.36 | 1,069,943 |
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 600 | $327.88 | 1,069,343 |
| Feb 12, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 1,000 | $328.50 | 1,068,343 |
| Dec 19, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,705 | $21.25 | 1,068,343 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.